Scholar Rock Holding Corporation’s SRRK share price has dipped by 5.79%, which has investors questioning if this is right ...

Biotech stock Scholar Rock (NASDAQ: SRRK) was popular among investors on Wednesday after a positive new analyst note on the ...

Scholar Rock Holding Corporation's apitegromab shows promise for SMA treatment, aims for 2025 launch. Click for my updated ...

Pundit Allison Bratzel is quite bullish on its leading drug candidate. Scholar Rock targets relatively uncommon disorders that might lack effective treatments. Its current lead drug candidate ...

CAMBRIDGE, Mass., April 18, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular ...

Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other ...

CAMBRIDGE, Mass., April 18, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular ...

On Wednesday, Piper Sandler reiterated an Overweight rating and a $42.00 price target on Scholar Rock stock (NASDAQ:SRRK), as analysts anticipate the company’s upcoming Q2 2025 proof-of-concept ...

Regulatory Milestones: BLA for apitegromab submitted in the US in January; MAA submission in the EU on track for March. Scholar Rock Holding Corp (NASDAQ:SRRK) is on track to launch apitegromab, a ...

Scholar Rock Stock Down 1.6 % Shares of NASDAQ SRRK opened at $32.84 on Friday. The stock has a market capitalization of $3.11 billion, a P/E ratio of -13.97 and a beta of 0.59. Scholar Rock ...